151 related articles for article (PubMed ID: 36916531)
1. Do patients with metastatic pancreatic adenocarcinoma to the lung have improved survival?
Ebrahimi A; Cham J; Puglisi L; De Shadarevian M; Hermel DJ; Spierling Bagsic SR; Sigal D
Cancer Med; 2023 May; 12(9):10243-10253. PubMed ID: 36916531
[TBL] [Abstract][Full Text] [Related]
2. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection.
Ilmer M; Schiergens TS; Renz BW; Schneider C; Sargut M; Waligora R; Weniger M; Hartwig W; Ceyhan GO; Friess H; Werner J; D'Haese JG
Surg Oncol; 2019 Dec; 31():16-21. PubMed ID: 31473583
[TBL] [Abstract][Full Text] [Related]
3. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas.
Downs-Canner S; Zenati M; Boone BA; Varley PR; Steve J; Hogg ME; Zureikat A; Zeh HJ; Lee KK
J Surg Oncol; 2015 Jul; 112(1):80-5. PubMed ID: 26153355
[TBL] [Abstract][Full Text] [Related]
4. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
Shi HJ; Jin C; Fu DL
World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
[TBL] [Abstract][Full Text] [Related]
5. Isolated pulmonary metastases in pancreatic ductal adenocarcinoma: a review of current evidence.
Adekolujo OS; Wahab A; Akanbi MO; Oyasiji T; Hrinczenko B; Alese OB
Cancer Biol Ther; 2023 Dec; 24(1):2198479. PubMed ID: 37526431
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis.
Oweira H; Petrausch U; Helbling D; Schmidt J; Mannhart M; Mehrabi A; Schöb O; Giryes A; Decker M; Abdel-Rahman O
World J Gastroenterol; 2017 Mar; 23(10):1872-1880. PubMed ID: 28348494
[TBL] [Abstract][Full Text] [Related]
7. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis.
Mackay TM; van Erning FN; van der Geest LGM; de Groot JWB; Haj Mohammad N; Lemmens VE; van Laarhoven HW; Besselink MG; Wilmink JW;
Eur J Cancer; 2019 Jan; 106():99-105. PubMed ID: 30476732
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study.
Decoster C; Gilabert M; Autret A; Turrini O; Oziel-Taieb S; Poizat F; Giovannini M; Viens P; Iovanna J; Raoul JL
Oncotarget; 2016 Jul; 7(29):45649-45655. PubMed ID: 27286454
[TBL] [Abstract][Full Text] [Related]
9. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Cheng SH; Cheng YJ; Jin ZY; Xue HD
Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
[TBL] [Abstract][Full Text] [Related]
10. Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival.
Groot VP; Blair AB; Gemenetzis G; Ding D; Burkhart RA; van Oosten AF; Molenaar IQ; Cameron JL; Weiss MJ; Yang SC; Wolfgang CL; He J
HPB (Oxford); 2019 Aug; 21(8):998-1008. PubMed ID: 30777697
[TBL] [Abstract][Full Text] [Related]
11. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
12. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
13. Impact of Driver Mutations on the Evolution of Isolated Metachronous Lung Metastasis of Pancreatic Ductal adenocarcinoma.
Vitellius C; Griveaux O; Morvant B; Pedrono E; Venara A; Ingster O; Baize N; Dincuff E; Rousselet MC; Guardiola P; Caroli-Bosc FX
Mol Diagn Ther; 2020 Aug; 24(4):443-449. PubMed ID: 32524539
[TBL] [Abstract][Full Text] [Related]
14. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
[TBL] [Abstract][Full Text] [Related]
15. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
16. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.
Lovecek M; Skalicky P; Chudacek J; Szkorupa M; Svebisova H; Lemstrova R; Ehrmann J; Melichar B; Yogeswara T; Klos D; Vrba R; Havlik R; Mohelnikova-Duchonova B
World J Gastroenterol; 2017 Sep; 23(35):6420-6428. PubMed ID: 29085191
[TBL] [Abstract][Full Text] [Related]
17. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior.
Sahin IH; Elias H; Chou JF; Capanu M; O'Reilly EM
BMC Cancer; 2018 Jul; 18(1):769. PubMed ID: 30055578
[TBL] [Abstract][Full Text] [Related]
19. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.
Dorman K; Gerckens M; Kruger S; Krueger K; Mayer Z; Rupp A; Zhang D; Weiss L; Westphalen CB; Haas M; Guenther M; Ormanns S; Klawonn F; Werner J; von Bergwelt-Baildon M; Heinemann V; Boeck S; Holdenrieder S
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2463-2474. PubMed ID: 35737090
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Akahori T; Sho M; Yanagimoto H; Satoi S; Nagai M; Nishiwada S; Nakagawa K; Nakamura K; Yamamoto T; Hirooka S; Yamaki S; Ikeda N
Oncologist; 2019 Jun; 24(6):749-e224. PubMed ID: 30679316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
